An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers With Different CYP2D6 Genotype.

Trial Profile

An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers With Different CYP2D6 Genotype.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2010

At a glance

  • Drugs Ispronicline (Primary) ; Ispronicline (Primary)
  • Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders
  • Focus Pharmacokinetics
  • Acronyms MB
  • Most Recent Events

    • 17 Nov 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Actual patient number (9) added as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top